For patients with atopic dermatitis, dupilumab treatment is associated with rapid and sustained disease control for up to 12 months, according to a study published online Dec. 15 in JAMA Dermatology.

Bruce Strober, M.D., Ph.D., from the Yale University School of Medicine in New Haven, Connecticut, and colleagues examined self-reported disease control and quality of life after dupilumab initiation in patients with atopic dermatitis. An online survey was administered at baseline and at one, two, three, six, nine, and 12 months after dupilumab initiation in 699 patients with moderate-to-severe atopic dermatitis; 632 and 483 patients completed the survey at months 1 and 12, respectively.

The researchers found that most patients achieved adequate disease control (Atopic Dermatitis Control Tool total score) at month 1, with further improvement by month 12 (60.9 and 77.4 percent, respectively, versus 5.3 percent at baseline). Compared with baseline, at each follow-up, use of other atopic dermatitis therapies was reduced, including topical and systemic corticosteroids. Patient satisfaction with atopic dermatitis treatment was higher at each follow-up than at baseline (17.7 percent), reaching 85.1 percent at month 12. Compared with baseline, at each follow-up, patients reported reductions in flare, itch, and skin symptoms and improved sleep, health-related quality of life, and daily activities.

"This large-scale, 12-month study of dupilumab in the United States provides evidence of patient-reported benefits of dupilumab for controlling atopic dermatitis and its symptoms in the clinical practice setting," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry, including Sanofi and Regeneron Pharmaceuticals, which manufacture dupilumab and funded the study.

Abstract/Full Text (subscription or payment may be required)